303 related articles for article (PubMed ID: 16321982)
1. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
Tsukahara T; Tsukahara R; Yasuda S; Makarova N; Valentine WJ; Allison P; Yuan H; Baker DL; Li Z; Bittman R; Parrill A; Tigyi G
J Biol Chem; 2006 Feb; 281(6):3398-407. PubMed ID: 16321982
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.
Cheng Y; Makarova N; Tsukahara R; Guo H; Shuyu E; Farrar P; Balazs L; Zhang C; Tigyi G
Cell Signal; 2009 Dec; 21(12):1874-84. PubMed ID: 19709640
[TBL] [Abstract][Full Text] [Related]
3. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
4. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
5. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.
Step SE; Lim HW; Marinis JM; Prokesch A; Steger DJ; You SH; Won KJ; Lazar MA
Genes Dev; 2014 May; 28(9):1018-28. PubMed ID: 24788520
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
7. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.
Simon MF; Daviaud D; Pradère JP; Grès S; Guigné C; Wabitsch M; Chun J; Valet P; Saulnier-Blache JS
J Biol Chem; 2005 Apr; 280(15):14656-62. PubMed ID: 15710620
[TBL] [Abstract][Full Text] [Related]
9. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
10. Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.
Álvarez-Almazán S; Bello M; Tamay-Cach F; Martínez-Archundia M; Alemán-González-Duhart D; Correa-Basurto J; Mendieta-Wejebe JE
Biochem Pharmacol; 2017 Oct; 142():168-193. PubMed ID: 28716729
[TBL] [Abstract][Full Text] [Related]
11. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
[TBL] [Abstract][Full Text] [Related]
12. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.
Fujimura T; Sakuma H; Ohkubo-Suzuki A; Aramori I; Mutoh S
Biol Pharm Bull; 2006 Mar; 29(3):423-9. PubMed ID: 16508139
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
Polikandriotis JA; Mazzella LJ; Rupnow HL; Hart CM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1810-6. PubMed ID: 16020752
[TBL] [Abstract][Full Text] [Related]
15. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
16. Ligand Activity of Group 15 Compounds Possessing Triphenyl Substituent for the RXR and PPARγ Nuclear Receptors.
Hiromori Y; Ido A; Aoki A; Kimura T; Nagase H; Nakanishi T
Biol Pharm Bull; 2016; 39(10):1596-1603. PubMed ID: 27725436
[TBL] [Abstract][Full Text] [Related]
17. Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha.
Li Y; Kovach A; Suino-Powell K; Martynowski D; Xu HE
J Biol Chem; 2008 Jul; 283(27):19132-9. PubMed ID: 18469005
[TBL] [Abstract][Full Text] [Related]
18. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
19. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
